Noonan Syndrome Clinical Trial
Official title:
Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome
1. Clinical Objective : To improve the growth of these children
2. Genetic objective : A study of the genetics of the syndrome
| Status | Completed |
| Enrollment | 36 |
| Est. completion date | July 2010 |
| Est. primary completion date | July 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 3 Years to 15 Years |
| Eligibility |
Inclusion Criteria: - Children and adolescents with Noonan's syndrome with a height < -2 SD and no progressive cardiopathy Exclusion Criteria: - Age < 3 years - Height = -2 SD The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| France | Sanofi-Aventis | Paris |
| Lead Sponsor | Collaborator |
|---|---|
| Sanofi |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Evaluation of height : gain in height and rate of growth | at each visit (every 3 months) or every 6 months | No | |
| Secondary | Clinical and laboratory test safety | every 6 months | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01529944 -
Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658
|
Phase 3 | |
| Recruiting |
NCT05761314 -
Solid Tumors in RASopathies
|
N/A | |
| Recruiting |
NCT04463316 -
GROWing Up With Rare GENEtic Syndromes
|
||
| Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
| Enrolling by invitation |
NCT05308927 -
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
|
||
| Recruiting |
NCT04395495 -
RASopathy Biorepository
|
||
| Completed |
NCT01529840 -
Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT06355622 -
Prevalence and Characterization of Pain in RASopathies
|
N/A | |
| Recruiting |
NCT05202210 -
Constitution of a Biological Collection to Study the Pathophysiology in Noonan Syndrome
|
||
| Completed |
NCT02713945 -
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT05361811 -
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
|
N/A | |
| Completed |
NCT03435627 -
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)
|
||
| Recruiting |
NCT05723835 -
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
|
Phase 3 | |
| Completed |
NCT02486731 -
Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes
|
||
| Completed |
NCT01927861 -
Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome
|
Phase 3 | |
| Recruiting |
NCT04888936 -
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies
|
||
| Recruiting |
NCT06331117 -
Effect of RAS/MAPK Pathway Hyperactivation on Growth' and Bone' Profile of the RASopathies
|
N/A | |
| Completed |
NCT00960128 -
Observational Prospective Study on Patients Treated With Norditropin®
|
N/A | |
| Terminated |
NCT00351221 -
Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome
|
Phase 2 |